Litcius/Paper detail

Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation

Madoka Koyanagi, Satoshi Imai, Yuki Iwamitsu, Mayuna Matsumoto, Mamiko Saigo, Akari Moriya, Takashi Ogihara, Yui Nakazato, Atsushi Yonezawa, Shunsaku Nakagawa, Takayuki Nakagawa, Kazuo Matsubara

2021Neuropharmacology25 citationsDOI

Topics & Concepts

PaclitaxelCilostazolChemotherapy-induced peripheral neuropathyMedicineSchwann cellPeripheral neuropathyPharmacologyPhosphodiesteraseCancerCancer researchInternal medicineEndocrinologyChemistryPathologyAspirinBiochemistryDiabetes mellitusEnzymeCancer Treatment and PharmacologyHER2/EGFR in Cancer ResearchMultiple Myeloma Research and Treatments
Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation | Litcius